Merge Technologies of Milwaukee last month signed an agreement with ADAC Laboratories of Milpitas, CA, in which ADAC will expand its distribution of Merge products. The agreement includes Merge’s DICOM products for ADAC businesses such as nuclear
Merge Technologies of Milwaukee last month signed an agreement with ADAC Laboratories of Milpitas, CA, in which ADAC will expand its distribution of Merge products. The agreement includes Merges DICOM products for ADAC businesses such as nuclear medicine, remanufacturing, radiation treatment planning, and healthcare information systems. The deal is part of Merges strategy to grow its distribution channels through partnerships with OEMs and VARs, according to company executives. Both companies expect the agreement to enhance their growth by giving Merge access to ADACs markets, and ADAC access to DICOM conversion systems for its products.
In other Merge news, the company this month announced preliminary fourth-quarter financial results that were well below analyst projections. Revenue is expected to be between $2 million and $2.3 million for the quarter, compared with revenue of $2.9 million for the same period last year. Merge believes its net loss will be between 19¢ and 22¢ per share. First Call had expected a profit of 2¢ per share for the quarter.
For the year, Merge expects revenue to be between $9.4 million and $9.7 million, compared with $9.7 million posted in 1997. The firm expects a net loss of 35¢ to 38¢ per share, compared with a net loss of 5¢ recorded last year. Merges stock closed at a price of $1.19 on Jan. 13, down 80.2% from its initial public offering price of $6 in January 1998.
Both direct and OEM/VAR sales underperformed during the period, according to the company. The company is reorganizing its sales staff to address its end-user sales difficulties and is redoubling its efforts to improve its OEM/VAR activities, said president and CEO William Mortimore.
Can CT-Based AI Provide Automated Detection of Colorectal Cancer?
February 14th 2025For the assessment of contrast-enhanced abdominopelvic CT exams, an artificial intelligence model demonstrated equivalent or better sensitivity than radiologist readers, and greater than 90 percent specificity for the diagnosis of colorectal cancer.
Key Chest CT Parameters for Body Composition May be Prognostic for Patients with Resectable NSCLC
February 11th 2025A high intermuscular adipose index has a 49 percent increased likelihood of being associated with lower overall survival in patients with resectable non-small cell lung cancer (NSCLC), according to new research.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Comparative AI Study Shows Merits of RapidAI LVO Software in Stroke Detection
February 6th 2025The Rapid LVO AI software detected 33 percent more cases of large vessel occlusion (LVO) on computed tomography angiography (CTA) than Viz LVO AI software, according to a new comparative study presented at the International Stroke Conference (ISC).
New CT Angiography Study Shows Impact of COVID-19 on Coronary Inflammation and Plaque
February 5th 2025Prior COVID-19 infection was associated with a 28 percent higher progression of total percent atheroma volume (PAV) annually and over a 5 percent higher incidence of high-risk plaque in patients with coronary artery lesions, according to CCTA findings from a new study.